Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
Resources
Press Release, 15 July 2021
Adhoc Press Release
Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals
23rd Ordinary General Meeting, 2021
Meeting minutes German version
Press Release, 22 June 2021
Kuros Biosciences announces publication of data on MagnetOs in eCM Journal linking MOA to enhanced predictable bone regeneration
Press Release, 17 June 2021
Kuros Biosciences to present at upcoming U.S. spine conferences
Press Release, 2 June 2021
Kuros Biosciences’s commercial roll-out of MagnetOs bone graft exceeds expectations
Press Release, 17 May 2021
Kuros to receive $4 million milestone payment from Checkmate Pharmaceuticals